08.04.26 -- CDMO Capacity Remains Tight — How To Avoid A Costly Partner Mistake

Understanding when to leverage GMP vs non-GMP stability studies and where each approach delivers maximum value can help sponsors make better development decisions and reach clinic faster.

Standardized latex bead references combined with negative stain TEM provide precise viral particle characterization and consistent viral load quantification.

Discover how solvent‑free, solid‑state stress testing speeds degradation studies, yields realistic impurity profiles, and provides earlier, material‑efficient insight into drug stability and risk.

Particle counts don’t manage risk. Biologics need particle ID and forensic insight to separate benign artifacts from real threats and guide early decisions.

Advanced cell line strategies improve stability and chain pairing while accelerating production, helping developers overcome scalability, productivity, and timeline challenges.

Emerging fill-finish technologies improve sterility, quality control, and flexibility while enabling prefilled systems and biologics scale-up.

A strategic framework outlines ten critical questions to evaluate a manufacturing partner’s reliability, expertise, performance, and operational rigor to ensure successful, scalable cell‑therapy development.

Explore where tech transfer and validation commonly falter, and how disciplined execution helps teams maintain control through PPQ and beyond.

Accelerate your path to IND and FiH with AI-driven design, advanced cell line engineering, and intensified processes delivering high titers in 9–14 months.

Blending pharmaceuticals and medical devices into a single product offers immense potential for patient care, but manufacturing these combination products presents unique hurdles.

Facing challenges transferring your biological product from development to manufacturing? Delve into strategies for tech transfer processes, ensuring regulatory compliance, quality, and consistency.